CVS Launches Cordavis To Make US Biosimilars More Accessible, Affordable

First Partner Is Sandoz For Adalimumab Product

CVS Health’s new subsidiary Cordavis will help manufacturers produce and/or commercialize biosimilars with the aim of reducing overall drug costs while improving access to and affordability of medicines.

CVS Health office in Chandler, AZ
CVS will get into biosimilars via subsidiary Cordavis • Source: Shutterstock

Pharmacy giant CVS Health Corp. has launched a wholly owned subsidiary called Cordavis to work directly with manufacturers to commercialize and/or produce biosimilars. The subsidiary will build a portfolio of products with the aim of improving access to biosimilars and affordability in the US. CVS said in its announcement late on 23 August that creating more competition should drive down product prices in the US biosimilar market, which is projected to grow from less than $10bn in 2022 to more than $100bn in 2029.

It remains to be seen whether increased competition in the biosimilar space is the key to boosting overall growth of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.